C3L-00993
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 75.59206023
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.600
- MYC_TARGETS_V2+0.580
- E2F_TARGETS+0.530
- OXIDATIVE_PHOSPHORYLATION+0.510
- G2M_CHECKPOINT+0.440
- DNA_REPAIR+0.410
- SPERMATOGENESIS+0.310
- UNFOLDED_PROTEIN_RESPONSE+0.280
- MTORC1_SIGNALING+0.180
- FATTY_ACID_METABOLISM+0.170
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.530
- ALLOGRAFT_REJECTION-0.520
- COMPLEMENT-0.510
- INTERFERON_ALPHA_RESPONSE-0.500
- INFLAMMATORY_RESPONSE-0.470
- INTERFERON_GAMMA_RESPONSE-0.460
- KRAS_SIGNALING_UP-0.440
- COAGULATION-0.430
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.430
- ANGIOGENESIS-0.420
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR975602 | — | — | 0.947 |
| 2 | fea46737-a2b3-49d4-8358-d0737546b6da | — | — | 0.946 |
| 3 | AUR-AFR3-TTM1-A-1-1-R-A743-41 | — | C | 0.938 |
| 4 | TCGA-63-A5MY-01A-11R-A26W-07 | — | cohortSQ2 | 0.937 |
| 5 | 3d1f89ec-ac0b-40f8-ac89-ed0c2d4967b7 | — | — | 0.935 |
| 6 | SRR12475110 | — | — | 0.933 |
| 7 | TCGA-AN-A04D-01A-21R-A034-07 | — | E | 0.932 |
| 8 | TCGA-HD-A634-01A-11R-A28V-07 | — | — | 0.931 |
| 9 | 64935b9c-623d-40d4-bd89-f2af006b1f92 | — | — | 0.928 |
| 10 | 176e93be-1ae5-43f2-a0b5-17f31695e679 | — | — | 0.928 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.600 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.580 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.530 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.510 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.440 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.410 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.310 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.280 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.180 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| PEROXISOME | 0.150 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.130 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.070 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.040 | Inavolisib | — uncovered |